CVRx profit margin CVRX
Gross, operating and net profit as a share of revenue over the last twelve months, from 2025.
- Net margin, 12 months
- −84.9%
- Operating margin, 12 months
- −79.5%
- Net margin on a year earlier
- +10.7 pts
- Peer median
- 7.6%
Over the twelve months to Jun 30, 2026, CVRx kept −84.9% of its revenue as net profit, with an operating margin of −79.5% and a gross margin of 86.9%.
The median for 6 medical instruments and supplies stocks of a similar size is 7.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −94.1% | −90.5% | 85.3% |
| FY2024 | n/a | n/a | 83.8% |
| FY2023 | n/a | n/a | 84.1% |
| FY2022 | n/a | n/a | 77.8% |
| FY2021 | n/a | n/a | 72.1% |
| FY2020 | n/a | n/a | 76.2% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −84.9% | +10.7 pts | −79.5% | |
| Q1 FY26 | −89.1% | +8.3 pts | −84.6% | |
| Q4 FY25 | −94.1% | n/a | −90.5% | |
| Q3 FY25 | −92.9% | n/a | −90.0% | |
| Q2 FY25 | −95.6% | n/a | −93.5% | |
| Q1 FY25 | −97.5% | n/a | −95.9% | |
| Q4 FY24 | n/a | n/a | n/a | |
| Q3 FY24 | n/a | n/a | n/a | |
| Q2 FY24 | n/a | n/a | n/a | |
| Q1 FY24 | n/a | n/a | n/a | |
| Q4 FY23 | n/a | n/a | n/a | |
| Q3 FY23 | n/a | n/a | n/a |
Against its peers
Companies in Medical - Instruments & Supplies nearest CVRx's size, closest first, today.
| Company | Profit margin |
|---|---|
| CVRXCVRx | −84.9% |
| NEPHNephros | 8.4% |
| APTAlpha Pro Tech | 6.8% |
| KEQUKewaunee Scientific | 3.0% |
| PDEXPro DEX | 17.6% |
| UTMDUtah Medical Products | 29.0% |
| INFUInfuSystem | 6.0% |
| Peer median | 7.6% |
Where CVRx ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on CVRx
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.